Sponsored by News E. coli could be linked to bowel cancer in younger adults
Childhood exposure to a toxin produced by Escherichia coli (E. coli) could be contributing to the rise of bowel cancer in under-50s, according to research funded by Cancer Research UK. Produced by certain strains of E. coli that reside in the colon and rectum, colibactin is a toxin capable of altering DNA. An international team of researchers, led by the University of California San Diego, has found that exposure to colibactin in early childhood imprints a distinct genetic signature on the DNA of colon cells – one that may increase the risk of developing colorectal cancer before the age of 50. The new study, published in Nature, analysed 981
colorectal cancer genomes from patients with both early- and late-onset disease across 11 countries with varying colorectal cancer risk levels. The findings show that colibactin leaves behind specific patterns of DNA mutations that were 3.3 times more common in early-onset cases (specifically in adults under 40) than in those diagnosed after the age of 70. These mutation patterns were also particularly prevalent in countries with high incidence of early-onset cases. “These mutation patterns are a kind of historical
record in the genome, and they point to early-life exposure to colibactin as a driving force behind early-onset disease,” said study senior author Ludmil Alexandrov, professor in the Shu Chien- Gene Lay Department of Bioengineering and the Department of Cellular and Molecular Medicine at UC San Diego, who is also a member of UC San Diego Moores Cancer Center and Deputy Director
of Sanford Stem Cell Fitness and Space Medicine Center.
Although previous studies – including earlier
work from Alexandrov’s lab – have identified colibactin-related mutations in roughly 10% to 15% of all colorectal cancer cases, those studies either focused on late-onset cases or did not distinguish between early- and late-onset disease. This latest study is the first to demonstrate a substantial enrichment of colibactin-related mutations specifically in early-onset cases. The implications are sobering. Once considered a disease of older adults, colorectal cancer is now on the rise among young people in at least 27 countries. Its incidence in adults under 50 has roughly doubled every decade for the past 20 years. If current trends continue, colorectal cancer is projected to become the leading cause of
The Complete Solution for Sickle Cell Screening
cancer-related death among young adults by 2030. Until now, the reasons behind this surge have
remained unknown. Young adults diagnosed with colorectal cancer often have no family history of the disease and few known risk factors such as obesity or hypertension. That has fuelled speculation about potential hidden environmental or microbial exposures – something this new study directly investigates. “When we started this project, we weren’t planning to focus on early-onset colorectal cancer,” said study co-first author Marcos Díaz-Gay, a former postdoctoral researcher in Alexandrov’s lab. “Our original goal was to examine global
patterns of colorectal cancer to understand why some countries have much higher rates than others. But as we dug into the data, one of the most interesting and striking findings was how frequently colibactin-related mutations appeared in the early-onset cases,” Marcos continued. According to the team’s analysis, colibactin’s damaging effects begin early. By molecularly timing each mutational signature identified in this study, the researchers demonstrate that colibactin-associated mutations arise early in tumour development, consistent with prior studies showing that such mutations occur within the first 10 years of life. The study also reveals that colibactin-related mutations account for approximately 15% of what are known as APC driver mutations - some of the earliest genetic alterations that directly promote cancer development – in colorectal cancer.
Streamline and simplify your testing process with the trusted combination of SICKLEDEX®
and Sickle-Chex® SICKLEDEX® Solubility Kit
A fast, efficient, and easy-to-use qualitative test for detecting
sickling haemoglobins in human blood samples.
Results in just 6 minutes
Requires only 20 µL of patient or control sample
Dropper bottle format eliminates the need for pipettes
Sickle-Chex® . Quality Controls
Ensure consistent result reporting with stabilised human whole blood controls that mimic real patient samples.
100 day open-vial stability
Ready to use - no reconstitution needed
Compatible with SICKLEDEX® and other solubility test kits
Choose confidence, convenience and consistency. Find out more at:
alphalabs.co.uk/sicklecell
www.alphalabs.co.uk 023 8048 3000
info@alphalabs.co.uk
02 Sickle Cell - 180x94 - April
2025.indd 1 02/05/2025 14:59:24 June 2025 I
www.clinicalservicesjournal.com 13
fusebulb -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
